Tests tinzaparin to prevent blood clots in advanced pancreatic cancer
Tests whether tinzaparin blood-clot prevention affects cancer progression in adults with advanced pancreatic cancer.
Key facts
- Who runs it
- Institute Of Molecular Medicine And Biomedical Research
- Where
- athens, Athens, and Thessaloniki, GreeceSee the 6 sites
- Registry title
- The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 450 people, planned
- Started
- 11 Apr 2022
- Planned end
- 13 Aug 2025
- Type of study
- Interventional
- Record updated
- 23 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spread pancreatic cancer who are about to start first treatment with chemotherapy (NabG). It studies whether a blood-thinning drug, tinzaparin, to prevent blood clots affects how long the disease stays stable.
- Age
- From 18 years. The record also lists an upper age limit of 64 years.
- Sex
- All sexes can join.
- Disease stage
- Pancreatic cancer that has grown locally and cannot be removed, or has spread (metastatic), confirmed by tissue and imaging tests. General fitness score (ECOG) 0-2. Life expectancy more than 6 months.
- Earlier treatment
- No earlier chemotherapy for this cancer: the person plans to start first-line chemotherapy with NabG.
Main reasons for not taking part
- Cannot take blood thinners, for example allergy, past heparin-induced low platelets (HIT II), active major bleeding or septic endocarditis
- Poor kidney function (creatinine clearance below 20 mL/min) or platelet count below 50 G/L
- Poor liver function (AST/ALT above 5 x ULN or bilirubin above 2 x ULN)
- Surgery in the last month, or heart attack, other artery clot or stroke in the last month
- Already on long-term blood thinners or dual anti-platelet treatment, or pregnant or breastfeeding
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Locally Advanced or metastatic PC (confirmed by the recommended histological and imaging methods)
- Age ≥ 18 years
- Planning to start 1st line chemotherapy with NabG
- Eastern Cooperative Group (ECOG) 0-2
- Life expectancy >6 months
- Written informed consent
Who cannot take part
- Recent (< 1 month) oncological surgery, major abdominal or thoracic surgery, major orthopedic surgery, vascular surgery
- Severe concomitant disease that as per investigator's judgement is not compatible with participation in the study
- Subjects with contraindication to receive anticoagulant: a. Any hypersensitivity to anticoagulant or excipients. b. History of heparin-induced thrombocytopenia type II (HIT II). c. Active major bleeding or pre-diathesis for major bleeding d. Septic endocarditis
- Recent (< 1 month) acute coronary syndrome or any other arterial thrombosis, thrombotic or hemorrhagic stroke
- Creatinine clearance <20 mL/min according to Cockcroft-Gault formula
- Platelet count < 50 G/L at inclusion
- Hepatic dysfunction defined as at least one of the following: AST and/or ALT > 5 x ULN, bilirubin > 2 x ULN
- Patients on chronic anticoagulation or on dual anti-platelet treatment
- Pregnancy/lactation or insufficient contraception during the study and up to 3 months after the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Greece
- Athens Medical Group, Psychiko Clinicathens, GreeceNot yet recruiting
- 401 General Military Hospital of AthensAthens, GreeceNot yet recruiting
- Attikon University HospitalAthens, GreeceNot yet recruiting
- Bioclinic S.A.Thessaloniki, GreeceNot yet recruiting
- Papageorgiou HospitalThessaloniki, GreeceNot yet recruiting
- Theageneio Cancer HospitalThessaloniki, GreeceNot yet recruiting
About the trial
What the trial wants to find out
•Evaluate the impact of VTE prevention on progression-free survival (PFS). •Investigate the efficacy of long term VTE prevention with simultaneously administration of tinzaparin during 1st line chemotherapy in patients undergoing anticancer treatment with NabG for locally advanced or metastatic PC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
- Plain-language title
- Tests tinzaparin to prevent blood clots in advanced pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-520043-17-00, who can take part
- Record updated
- 23 January 2025